mono-N,N-dimethylamide of succinic acid | 131566-92-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: mono-N,N-dimethylamide of succinic acid
• 英文别名: N,N-dimethyl-succinic diamide；N-Dimethylamino-succinamid；N',N'-dimethylbutanediamide
• CAS: 131566-92-2
• 化学式: C₆H₁₂N₂O₂
• mdl: MFCD19205261
• 分子量: 144.173
• InChiKey: DDJYVUZXVOTIHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  153 °C
• 沸点：
  346.4±25.0 °C(Predicted)
• 密度：
  1.086±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  mono-N,N-dimethylamide of succinic acid 、 甲胺 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 生成 N,N,N'-Trimethyl-succinamid
  参考文献：
  名称：

  Conformation-directing effects of a single intramolecular amide-amide hydrogen bond: variable-temperature NMR and IR studies on a homologous diamide series

  摘要：

  We have studied intramolecular hydrogen bonding in a homologous series of diamides (compounds 1-6) in methylene chloride, 9:1 carbon tetrachloride/benzene, and acetonitrile. By correlating variable-temperature H-1 NMR and IR measurements, we have shown that the temperature dependence of the amide proton NMR chemical shift (DELTA-delta/DELTA-T) can provide qualitative (and in some cases quantitative) information on the thermodynamic relationship between the intramolecularly hydrogen bonded and non-hydrogen-bonded states of flexible molecules. Among the hydrogen-bonded ring sizes represented in the diamide series, the intramolecular interaction is particularly enthalpically favorable in the nine-membered hydrogen-bonded ring (compound 4). Variable-temperature IR and NMR data indicate that the internally hydrogen bonded state of diamide 4 is 1.4-1.6 kcal/mol more favorable enthalpically than the non-hydrogen-bonded state, in methylene chloride solution; the non-hydrogen-bonded state is 6.8-8.3 eu more favorable entropically in this solvent. In contrast, there appear to be much smaller enthalpy differences between the internally hydrogen bonded and non-hydrogen-bonded states of diamides 2 and 3. Our findings are important methodologically because the temperature dependences of amide proton chemical shifts are commonly used to elucidate peptide conformation in solution. Our results show that previous "rules" for the interpretation of such data are incomplete. In non-hydrogen-bonding solvents, small amide proton DELTA-delta/DELTA-T values have been taken to mean that the proton is either entirely free of hydrogen bonding or completely locked in an intramolecular hydrogen bond over the temperature range studied. We demonstrate that an amide proton can be equilibrating between intramolecularly hydrogen bonded and non-hydrogen-bonded states and still manifest a small chemical shift temperature dependence (implying that the hydrogen-bonded and non-hydrogen-bonded states are of similar enthalpy).

  DOI：

  10.1021/ja00004a016
• 作为产物：
  描述：

  丁二酰亚胺 、 二甲胺 20.0 ℃ 、100.0 kPa 条件下， 以100%的产率得到mono-N,N-dimethylamide of succinic acid
  参考文献：
  名称：

  胺与羰基化合物和异硫氰酸酯的定量固相反应

  摘要：

  据报道，气态或固态胺与醛的一系列固相反应生成亚胺，固态酸酐生成二酰胺（由酰亚胺生成）或酰胺羧酸盐或酰亚胺，固态酰亚胺生成二酰胺，与固态内酯或碳酸盐生成固态反应。得到官能化的氨基甲酸酯，与聚碳酸酯得到降解的氨解，和与固体异硫氰酸酯得到硫脲。二酰胺通过固态热解或酸催化作用生成酰亚胺。据报道，各种双反应，两步反应，3级反应和顺序反应均处于固态而不熔化。在53个已报告的反应实例中，产率是定量的，并且在100％产率的反应中无需进行后处理（除了四次洗涤）。最初的三个固态反应但与液态产物的反应不是定量的。升至公斤级显示了该技术在大规模应用中的前景。原子力显微镜的超显微分析通过三步法中影响深远的各向异性分子运动阐明了固态机制。还使用AFM研究了聚碳酸酯的气固氨基分解酶。讨论了对可持续化学的影响。

  DOI：

  10.1016/s0040-4020(00)00511-1

文献信息

• [EN] INHIBITORS OF APOL1 AND USE OF THE SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEUR UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2021252859A1

  公开（公告）日：2021-12-16

  The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

  本公开提供了至少一种化合物、重氢化衍生物或药用可接受的盐，选自公式(I)化合物、其重氢化衍生物以及任何前述物质的药用可接受的盐，包含同一的组成物，以及制造和使用同一的方法，包括用于治疗APOL1介导的肾脏疾病。
• LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS
  申请人：PARTHASARADHI REDDY Bandi

  公开号：US20110015196A1

  公开（公告）日：2011-01-20

  The invention relates to novel lupeol-type triterpene derivatives and related compounds, and pharmaceutical compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.

  这项发明涉及新型鲁皮醇类三萜衍生物及相关化合物，以及用于治疗病毒性疾病特别是HIV介导疾病的药物组合物。
• [EN] HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY<br/>[FR] DERIVES AMIDES HETEROCYCLIQUES POSSEDANT UNE ACTIVITE INHIBITRICE DE GLYCOGENE PHOSPHORYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2005018637A1

  公开（公告）日：2005-03-03

  A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example: R4 and R5 together are either -S-C(R6=C(R7)- or -C(R7)=C(R6)-S- ; R6 and R7 are independently selected from hydrogen and halo; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 is halo, cyano or carboxy; R2 is for example methyl; R3 is for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.

  该化合物的分子式为（1）或其药用可接受的盐或前药；（1）其中，例如：R4和R5一起是-S-C(R6=C(R7)-或-C(R7)=C(R6)-S-；R6和R7分别选择自氢和卤素；A是苯基或杂环芳基；n为0、1或2；R1为卤素、氰基或羧基；R2为例如甲基；R3为例如选择自卤(1-4C)烷基、二卤(1-4C)烷基、三氟甲基、羟基(1-4C)烷基、二羟基(2-4C)烷基、三羟基(3-4C)烷基、氰基(1-4C)烷基（在烷基上可选择性地取代羟基）、（1-4C)烷氧基(1-4C)烷基、（1-4C)烷氧基(1-4C)烷氧基(1-4C)烷基、二[(1-4C)烷氧](1-4C)烷基、(羟基)[(1-4C)烷氧](1-4C)烷基；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备化合物和含有它们的药物组合物的方法。
• Amide derivatives
  申请人：Brown S. Dearg

  公开号：US20050245551A1

  公开（公告）日：2005-11-03

  The invention concerns amide derivatives of Formula (Ia) wherein X is —NHCO— or —CONH—; m is 0-3; R 1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R 2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino and carboxy; R 3 is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino and N -(1-6C)alkyl-arylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及式(Ia)的酰胺衍生物，其中X为—NHCO—或—CONH—；m为0-3；R1为羟基、卤代、三氟甲基、氰基、巯基、硝基、氨基、羧基和氨基甲酰基等基团；n为0-2；R2为羟基、卤代、三氟甲基、氰基、巯基、硝基、氨基和羧基等基团；R3为氢、卤代、(1-6C)烷基或(1-6C)烷氧基；q为0-4；Q为芳基、芳氧基、芳基-(1-6C)烷氧基、芳基氨基和N-(1-6C)烷基-芳基氨基等基团；或其药学上可接受的盐或体内可降解的酯；制备它们的方法、含有它们的制药组合物以及它们在治疗细胞因子介导的疾病或医疗状况中的用途。
• Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20050239832A1

  公开（公告）日：2005-10-27

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  本发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和状况的方法。淀粉样变性是指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和状况的集合。